A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1¿ 50%

Registry ID

CINC280I12201

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2020-12-15

Completion date

2021-11-04

Last update

2020-02-17

Conditions

• LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER

Related clinical trials

• A PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN COMPARED TO STANDARD OF CARE IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON A THIRD-GENERATION EGFR TKI - ANDROMETA-LUNG-713
• A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALLCELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA)
• A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON¿SMALL CELL LUNG CANCER
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE STUDY OF DATOPOTAMAB DERUXTECAN OR DOCETAXEL IN PREVIOUSLY TREATED TROP2-POSITIVE ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG17)
• A PHASE 1/2 OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF BH-30643 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR AND/OR HER2 MUTATIONS (SOLARA)
• A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE, INTERNATIONAL STUDY OF DURVALUMAB PLUS DOMVANALIMAB (AB154) IN PARTICIPANTS WITH LOCALLY ADVANCED (STAGE III), UNRESECTABLE NON SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED FOLLOWING DEFINITIVE PLATINUM BASED CONCURRENT CHEMORADIATION THERAPY (PACIFIC 8)

View on source registry